• Predictors of Ovarian Insufficiency in Young Breast Cancer Patients

  NCT01197456

  CompletedObservationalUpdated Apr 22, 2020
• Predicting Response to Immunochemotherapy in Early Triple Negative Breast Cancer

  NCT07570524

  RecruitingObservationalUpdated Jul 10, 2026
• Intra-peritoneal Chemotherapy in Ovarian Cancer

  NCT02861872

  Unknown statusObservationalUpdated Aug 10, 2016
• The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

  NCT07187674

  Not yet recruitingInterventionalNot ApplicableUpdated Sep 23, 2025
• Exploring Gut Microbiome Differences in Female Cancer Patients With Varied Ovarian Function and Fertility Outcomes Following Immune Checkpoint Inhibitor Therapy

  NCT07201259

  Not yet recruitingObservationalUpdated Oct 1, 2025
• Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

  NCT05877859

  RecruitingObservationalUpdated May 7, 2026

ClinicalTrials.gov ID

NCT07527819

Lead Sponsor

Peter MacCallum Cancer Centre, AustraliaOTHER

Overall Status

Not yet recruiting

Study Type

Observational

Enrollment

75Estimated

Last Update Posted

Apr 14, 2026Actual

Start Date

Apr 8, 2026Estimated

Primary Completion Date

Apr 2031Estimated

Completion Date

Dec 31, 2031Estimated

Official Title

Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)

Brief Summary

This study aims to collect information about the effects of chemotherapy combined with immunotherapy (immune checkpoint inhibitors) for early-stage triple-negative breast cancer (TNBC) on ovarian function and fertility.

You may be eligible for this study if you have been diagnosed with early-stage TNBC and are planning to receive neoadjuvant chemotherapy combined with immunotherapy before surgery. Additional eligibility criteria apply.

Participants who choose to enroll will be asked to complete questionnaires and provide blood samples before and after treatment to measure hormone levels related to ovarian function. Information about menstrual patterns, fertility preservation discussions, and reproductive health will also be collected. Some participants may undergo ultrasound assessments to evaluate ovarian reserve and endometrial thickness. Follow-up will continue for up to 24 months after treatment to assess long-term ovarian function.

No additional or experimental cancer treatments will be provided as part of this study. This is an observational study only, and participants will receive standard cancer treatment as recommended by their treating team.

It is hoped this research will provide important information about the potential effects of chemotherapy and immunotherapy on ovarian health and fertility in women receiving treatment for early-stage TNBC.

Detailed Description

Patients will be asked to consent to the future use of their biological samples collected during the trial. Samples will be securely stored at Peter MacCallum Cancer Centre, coded, and linked to clinical data. Patients can request sample destruction at any time, but past analyses cannot be undone.

The Sponsor or delegate will manage trial data, while sites are responsible for data entry and resolving queries. Data will be entered into REDCap, a secure system hosted by Peter MacCallum Cancer Centre. Site staff will be trained, and only authorized personnel listed on the delegation log may complete eCRFs.

• Triple Negative Breast Cancer (TNBC)

Ages Eligible for Study

Adult (18-64)

Sexes Eligible for Study

Female

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Patient has provided written informed consent using the FERTILE Patient Information and Consent form (PICF)
2. Early-stage TNBC (definition determined as per clinicians' discretion)
3. Female patients between 18 and 42 years of age
4. Planned to receive at least one dose of neoadjuvant chemotherapy-ICI with a PD-(L)1 inhibitor including but not limited to pembrolizumab, atezolizumab, durvalumab or nivolumab
5. Planned to receive gonadotrophin releasing hormone (GnRH) agonist with neoadjuvant chemotherapy

Exclusion Criteria:

1. Previous removal of both ovaries or ovarian ablation (such as bilateral ovarian radiotherapy)
2. Patients who have previously received immunotherapy or chemotherapy prior to registration
3. Receiving or planned to receive adjuvant endocrine therapy Note: patients using GnRH agonist for POI prevention are not excluded
4. Post-menopausal as defined by the investigator
5. Presence of any psychological, social, geographical, or other condition for which, in the opinion of the site Investigator, participation would not be in the best interest of the patient (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Peter MacCallum Cancer Centre, AustraliaOTHER

Collaborators

Hunter Medical Research Institute (HMRI)UNKNOWN

Royal Melbourne Hospital, AustraliaUNKNOWN

Monash HealthOTHER

Eastern HealthOTHER

Mater Hospital SydneyUNKNOWN

Chris O'Brien LifehouseUNKNOWN

Lyell McEwin HospitalOTHER_GOV

Sir Charles Gairdner HospitalOTHER

Integrated Haematology and Oncology NetworkOTHER

louise.nott@ths.tas.gov.au

Iris.Tung@easternhealth.org.au

michelle@mcc.net.au

wanda.cui@petermac.org